Form 144 - Report of proposed sale of securities:
SEC Accession No. 0001950047-25-003780
Filing Date
2025-06-03
Accepted
2025-06-03 17:14:03
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 144  
1 primary_doc.xml 144 6686
  Complete submission text file 0001950047-25-003780.txt   8290
Mailing Address 7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM United Kingdom SW1H 0DB
Business Address 7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM United Kingdom SW1H 0DB 441-295-5950
Roivant Sciences Ltd. (Subject) CIK: 0001635088 (see all company filings)

EIN.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: 144 | Act: 33 | File No.: 001-40782 | Film No.: 251020784
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 6TH FLOOR NEW YORK NY 10018
Business Address
Venker Eric (Reporting) CIK: 0001801917 (see all company filings)

Type: 144